Fig. 1 · Structure

Documents & Downloads

D609

Cat. No. A11388 CAS 83373-60-8

PC-PLC inhibitor

D609 is a selective competitive phosphatidyl choline-specific phospholipase C (PC-PLC) inhibitor (Ki = 6.4 μM); antiviral and antitumor agent.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

D609 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of D609 from 3 published references. In vitro models include ftRPE cells; SKBr3 cells. In vivo models include eight to ten week-old male ICR-CD1 mice.

D609 In Vitro Studies

In ftRPE cells, SI-D609 cotreatment, each at 10 μM, for 18 h or 24 h yielded viability higher than 95%, compared with under 20% following SI treatment. In SKBr3 cells, D609 at 50 μg/mL produced a 3.5-fold decrease in PC-PLC activity within 1 hour, maintained up to 72 hours. In a fluorescence-based assay using recombinant mouse ACE1 enzyme, D609 had a reported IC50 ± SEM of 31.05 ± 10.82 µM. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cell viability following cotreatment in ftRPE cells

Cell-based study · ftRPE cells [1]

ftRPE cells received SI-D609 cotreatment, each at 10 μM, for 18 h or 24 h. Viability was higher than 95% in the SI-D609 cotreatment group, compared with under 20% following SI treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viability tested by CCK8-kitcell viability D609 (10 μM), SI (10 μM), combination for 18 h or 24 h: higher than 95%[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
18 h or 24 h
Method
cotreatment
Co-treatment
Other interventions in this design: SI 10 μM. Compound effect isolated by the comparison: SI-D609 cotreatment group.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: D609

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > D609 inhibited the SI-induced ftRPE necrotic cell death (S24); Materials and methods > CCK8 assay (S113); Fig. 2 legend (S196)

cell viability tested by CCK8-kit: cell viability tested by CCK8-kit; comparator: SI treatment (10 μM) — Results > D609 inhibited the SI-induced ftRPE necrotic cell death (S24); Fig. 2 legend (S196)

PC-PLC activity in SKBr3 cells

Cell-based study · SKBr3 cells [2]

SKBr3 cells were incubated with D609 at 50 μg/mL. PC-PLC activity showed a 3.5-fold decrease within 1 hour, maintained up to 72 hours.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Relative PC-PLC activityRelative PC-PLC activity D609 (50 μg/mL): 3.5-fold decrease within 1 hour and maintained up to 72 hours[2]

Literature-Reported Treatment Conditions

Treatment concentration
50 μg/mL
Exposure duration
within 1 hour and was maintained up to 72 hours
Method
cell incubation with D609
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: D609

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > In vitro PC-PLC activity assay (S22); Results > PC-PLC inhibition induces downmodulation of HER2 expression on the SKBr3 plasma membrane (S53); Figure 3 legend (S132, S133)

Relative PC-PLC activity: Relative PC-PLC activity; comparator: untreated control cells — Results > PC-PLC inhibition induces downmodulation of HER2 expression on the SKBr3 plasma membrane (S53); Figure 3 legend (S133)

Fluorescence assay of recombinant mouse ACE1 inhibition

Biochemical assay · Recombinant mouse ACE1 enzyme [3]

Recombinant mouse ACE1 enzyme was pre-incubated with various compound concentrations and assessed using a fluorescence-based enzymatic assay against a DMSO control. The reported IC50 ± SEM was 31.05 ± 10.82 µM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Dose-response curves of the compounds obtained by fluorescence-based ACE enzymatic assayIC50 31.05 ± 10.82 µM[3]

Literature-Reported Treatment Conditions

Treatment concentration
various concentrations of compounds
Exposure duration
15 min at room temperature; 30 min at room temperature
Method
pre-incubated
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: D609

Evidence for D609 as the potassium form reported in the paper, not the free base/neutral form supplied as A11388; no salt equivalence, dose conversion or lot validation.

Results > Optimization of the HTS enzymatic assay (S25, S26); Results > Dose-response studies of the lead compounds against mACE (S40); Methods > Reagents for HTS assay (S196, S200); Methods > ACE enzymatic assay (S206, S208, S214); Table 1 (T1.h1, T1.r3)

Dose-response curves of the compounds obtained by fluorescence-based ACE enzymatic assay: Dose-response curves of the compounds obtained by fluorescence-based ACE enzymatic assay; comparator: DMSO control — Results > Dose-response studies of the lead compounds against mACE (S40); Table 1 (T1.h1, T1.r3)

D609 In Vivo Studies

Male ICR-CD1 mice received D609 at 75 µg/mouse by the intracerebroventricular route. Thermal stimulus responses showed increased %MPE, indicating modest analgesic potential. [3]

Thermal stimulus responses in mice

Animal study · Eight to ten week-old male ICR-CD1 mice [3]

Male ICR-CD1 mice received D609 at 75 µg/mouse by the intracerebroventricular route. D609 increased %MPE, indicating modest analgesic potential.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
latency to thermal stimulus and the results are expressed as %MPEReported result When administered at a lower 75 µg/mouse dose, D609 caused a similar increase in %MPE, confirming its modest analgesic potential[3]

Conditions shared by the study groups

Route
intracerebroventricular (i.c.v.) route
Vehicle
saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
D609 75 µg/mousecorresponding vehicle groupWhen administered at a lower 75 µg/mouse dose, D609 caused a similar increase in %MPE, confirming its modest analgesic potential[3]
D609 75 µg/mouse
Model: Eight to ten week-old male ICR-CD1 mice
Reported limits: Not stated in the sentences used: schedule.
Methods and source locations

Compound reported in the paper: D609

Evidence for D609 as the potassium form reported in the paper, not the free base/neutral form supplied as A11388; no salt equivalence, dose conversion or lot validation.

Results > In vivo behavior assay to assess pain perception > Tail flick assay (S72, S76, S79); Methods > Animals (S201); Methods > Acute analgesia measurement in response to thermal stimulus: tail-flick assay (S233)

latency to thermal stimulus and the results are expressed as %MPE: latency to thermal stimulus and the results are expressed as %MPE; comparator: corresponding vehicle group — Results > In vivo behavior assay to assess pain perception > Tail flick assay (S72, S79)

D609 75 µg/mouse · Results > In vivo behavior assay to assess pain perception > Tail flick assay (S72, S79)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 83373-60-8
Applications PC-PLC inhibitor
Formula C11H15KOS2
Molecular Weight 266.46
SMILES
S=C(S[K])OC1CC2C3C(CCC3)C1C2

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

D609 Research References

  1. [1] Wang B, Wang L, Gu S, et al. D609 protects retinal pigmented epithelium as a potential therapy for age-related macular degeneration. Signal Transduct Target Ther (2020). PMID: 32296021 DOI: 10.1038/s41392-020-0122-1 Source material
  2. [2] Paris L, Cecchetti S, Spadaro F, et al. Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells. Breast Cancer Res (2010). PMID: 20462431 DOI: 10.1186/bcr2575 Source material
  3. [3] Dobariya P, Williams J, Hanak F, et al. Exploiting the angiotensin-converting enzyme pathway to augment endogenous opioid signaling. Commun Biol (2025). PMID: 41087507 DOI: 10.1038/s42003-025-08790-6 Source material

Added to your cart

View Cart Checkout
Loading...